Replimune Stock Plummets After Second FDA Drug Rejection

FDA Rejection Sparks Massive Stock Sell-Off

Replimune Group's stock plunged nearly 60% in premarket trading on Monday. The sharp decline followed the U.S. Food and Drug Administration's issuance of a second Complete Response Letter for the company's advanced melanoma drug, RP1.

Overview of the Regulatory Setback

The FDA's decision marks the second time it has declined to approve RP1, an oncolytic virus therapy designed for use in combination with nivolumab. The regulatory agency's letter indicates that the application cannot be approved in its current form, creating significant uncertainty for the drug's development timeline.

Immediate Market Reaction and Impact

The market response was immediate and severe. By 05:10 ET, shares of Replimune had fallen more than 57% in premarket trading. This sell-off reflects a major loss of investor confidence in the therapy's approval prospects and has led to subsequent stock downgrades from analysts.

Summary and Future Outlook

The future for RP1 is now contingent on Replimune's ability to adequately address the concerns raised by the FDA. The company has not yet detailed its next steps, but investors will be closely monitoring for a strategic plan to navigate this significant regulatory hurdle.

Frequently Asked Questions

Q: Why did Replimune's stock price drop?
A: The stock dropped after the U.S. FDA rejected its melanoma drug, RP1, for a second time, by issuing a Complete Response Letter.

Q: What is RP1?
A: RP1 is an investigational oncolytic virus therapy developed by Replimune to treat advanced melanoma in combination with other drugs.

Source: Investing.com